Single-agent cis-platinum therapy for advanced ovarian cancer

David M. Gershenson, J. Taylor Wharton, Jay Herson, Creighton L. Edwards, Felix N. Rutledge

Research output: Contribution to journalArticle

Abstract

From May 1976 to July 1978, 100 patients with untreated stage III or IV ovarian carcinoma were entered into a prospective randomized clinical trial comparing melphalan, cis-platinum, hexamethylmelamine and cyclophosphamide, and a combination of hexamethylmelamine, cyclophosphamide, and doxorubicin hydrochloride (Adriamycin). The 22 patients who received cis-platinum, 18 of whom ultimately received hexamethylmelamine and cyclophosphamide therapy, are analyzed, and surgical and chemotherapeutic treatments are described. Response was evaluated by either clinical or surgical methods. Eleven of the 22 patients (50%) responded to cis-platinum treatment. Survival times ranged from 2 to 24 months, with a median survival time of 21.2 months. Gastrointestinal, hematologic, renal, and neurologic toxicities are reported; peripheral neuropathy constituted the major toxicity. Methods of alleviating or preventing neurotoxicity are discussed. It is concluded that cis-platinum as a single agent possesses definite activity against ovarian cancer.

Original languageEnglish (US)
Pages (from-to)487-496
Number of pages10
JournalObstetrics and Gynecology
Volume58
Issue number4
StatePublished - Jan 1 1981
Externally publishedYes

Fingerprint

Altretamine
Ovarian Neoplasms
Cisplatin
Cyclophosphamide
Doxorubicin
Melphalan
Survival
Peripheral Nervous System Diseases
Therapeutics
Nervous System
Randomized Controlled Trials
Carcinoma
Kidney

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Gershenson, D. M., Wharton, J. T., Herson, J., Edwards, C. L., & Rutledge, F. N. (1981). Single-agent cis-platinum therapy for advanced ovarian cancer. Obstetrics and Gynecology, 58(4), 487-496.

Single-agent cis-platinum therapy for advanced ovarian cancer. / Gershenson, David M.; Wharton, J. Taylor; Herson, Jay; Edwards, Creighton L.; Rutledge, Felix N.

In: Obstetrics and Gynecology, Vol. 58, No. 4, 01.01.1981, p. 487-496.

Research output: Contribution to journalArticle

Gershenson, DM, Wharton, JT, Herson, J, Edwards, CL & Rutledge, FN 1981, 'Single-agent cis-platinum therapy for advanced ovarian cancer', Obstetrics and Gynecology, vol. 58, no. 4, pp. 487-496.
Gershenson DM, Wharton JT, Herson J, Edwards CL, Rutledge FN. Single-agent cis-platinum therapy for advanced ovarian cancer. Obstetrics and Gynecology. 1981 Jan 1;58(4):487-496.
Gershenson, David M. ; Wharton, J. Taylor ; Herson, Jay ; Edwards, Creighton L. ; Rutledge, Felix N. / Single-agent cis-platinum therapy for advanced ovarian cancer. In: Obstetrics and Gynecology. 1981 ; Vol. 58, No. 4. pp. 487-496.
@article{3bf28ca3730041a28bb8707f9d0b3d5c,
title = "Single-agent cis-platinum therapy for advanced ovarian cancer",
abstract = "From May 1976 to July 1978, 100 patients with untreated stage III or IV ovarian carcinoma were entered into a prospective randomized clinical trial comparing melphalan, cis-platinum, hexamethylmelamine and cyclophosphamide, and a combination of hexamethylmelamine, cyclophosphamide, and doxorubicin hydrochloride (Adriamycin). The 22 patients who received cis-platinum, 18 of whom ultimately received hexamethylmelamine and cyclophosphamide therapy, are analyzed, and surgical and chemotherapeutic treatments are described. Response was evaluated by either clinical or surgical methods. Eleven of the 22 patients (50{\%}) responded to cis-platinum treatment. Survival times ranged from 2 to 24 months, with a median survival time of 21.2 months. Gastrointestinal, hematologic, renal, and neurologic toxicities are reported; peripheral neuropathy constituted the major toxicity. Methods of alleviating or preventing neurotoxicity are discussed. It is concluded that cis-platinum as a single agent possesses definite activity against ovarian cancer.",
author = "Gershenson, {David M.} and Wharton, {J. Taylor} and Jay Herson and Edwards, {Creighton L.} and Rutledge, {Felix N.}",
year = "1981",
month = "1",
day = "1",
language = "English (US)",
volume = "58",
pages = "487--496",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Single-agent cis-platinum therapy for advanced ovarian cancer

AU - Gershenson, David M.

AU - Wharton, J. Taylor

AU - Herson, Jay

AU - Edwards, Creighton L.

AU - Rutledge, Felix N.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - From May 1976 to July 1978, 100 patients with untreated stage III or IV ovarian carcinoma were entered into a prospective randomized clinical trial comparing melphalan, cis-platinum, hexamethylmelamine and cyclophosphamide, and a combination of hexamethylmelamine, cyclophosphamide, and doxorubicin hydrochloride (Adriamycin). The 22 patients who received cis-platinum, 18 of whom ultimately received hexamethylmelamine and cyclophosphamide therapy, are analyzed, and surgical and chemotherapeutic treatments are described. Response was evaluated by either clinical or surgical methods. Eleven of the 22 patients (50%) responded to cis-platinum treatment. Survival times ranged from 2 to 24 months, with a median survival time of 21.2 months. Gastrointestinal, hematologic, renal, and neurologic toxicities are reported; peripheral neuropathy constituted the major toxicity. Methods of alleviating or preventing neurotoxicity are discussed. It is concluded that cis-platinum as a single agent possesses definite activity against ovarian cancer.

AB - From May 1976 to July 1978, 100 patients with untreated stage III or IV ovarian carcinoma were entered into a prospective randomized clinical trial comparing melphalan, cis-platinum, hexamethylmelamine and cyclophosphamide, and a combination of hexamethylmelamine, cyclophosphamide, and doxorubicin hydrochloride (Adriamycin). The 22 patients who received cis-platinum, 18 of whom ultimately received hexamethylmelamine and cyclophosphamide therapy, are analyzed, and surgical and chemotherapeutic treatments are described. Response was evaluated by either clinical or surgical methods. Eleven of the 22 patients (50%) responded to cis-platinum treatment. Survival times ranged from 2 to 24 months, with a median survival time of 21.2 months. Gastrointestinal, hematologic, renal, and neurologic toxicities are reported; peripheral neuropathy constituted the major toxicity. Methods of alleviating or preventing neurotoxicity are discussed. It is concluded that cis-platinum as a single agent possesses definite activity against ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0019782801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019782801&partnerID=8YFLogxK

M3 - Article

C2 - 7024883

AN - SCOPUS:0019782801

VL - 58

SP - 487

EP - 496

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 4

ER -